Impaired glucose tolerance Impaired fasting glucose Type 2 diabetes Helicobacter pylori infection
Conditions
Interventions
HP eradication (Lansoprazole 60mg/day, AMPC 1500mg/day and CAM 800mg/day for 7days)
Sponsors
Chigasaki Municipal Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Patients with pre-diabetes or type 2 diabetes. 2) Patients with fasting plasma glucose <= 140mg/dl or HbA1c <= 8.0%(NGSP). 3) Patients with gastric or duodenal ulcer scar and HP infection.
Exclusion criteria
Exclusion criteria: 1)Patients who initiated or changed antidiabetic drugs within 3 months prior to the study entry. 2)Patients who initiated or changed antidyslipidemic drugs within 3 months prior to the study entry. 3)Patients who initiated or changed antiinflammatory drugs within 3 months prior to the study entry. 4)Patients receiving insulin therapy. 5)Patients with gastric or duodenal ulcer in the acute phase. 6)Patients with severe infection or severe trauma. 7)Patients with malignancy. 8)Patients during pregnancy or lactation. 9)Patients with severe liver dysfunction. 10)Patients with severe renal insufficiency. 11)Patients receiving steroid therapy. 12)Patients who were allergic to HP eradication drugs. 13)Patients incapable of informed consent. 14)Patients determined to be inappropriate by physician.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Insulin resistance (fasting serum insulin levels and homeostasis model assessment of insulin resistance (HOMA-IR)) at before and after HP eradication. | — |
Secondary
| Measure | Time frame |
|---|---|
| HbA1c, lipid profile, C reactive protein, body weight, body mass index and waist circumference at before and after HP eradication. | — |
Countries
Japan
Contacts
Public ContactYoshinobu Kondo
Chigasaki Municipal Hospital Department of Endocrinology and Metabolism
Outcome results
None listed